Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Candida Infection Testing Market Revenue Growth Supported By A CAGR Of 22.55% Through 2030
The market for candida infection testing experienced robust expansion lately, projecting a rise from $16.72 billion in 2025 to $17.8 billion by 2026, reflecting a compound annual growth rate of 6.4%. This growth during the past period was fueled by several factors, including a greater prevalence of fungal infections, an increasing number of patients with weakened immune systems, the broadening of diagnostic capabilities within hospitals, the widespread use of culture-based methods for fungal detection, and heightened awareness regarding antifungal drug resistance.
The market for candida infection testing is projected for robust expansion in the upcoming years, reaching an estimated value of $22.56 billion by 2030, propelled by a compound annual growth rate (CAGR) of 6.1%. This anticipated surge is underpinned by several key drivers, including heightened demand for swift fungal diagnostic solutions, a greater embrace of molecular and microbiome testing methodologies, the broadening availability of point-of-care fungal testing, increased investment in the sphere of infectious disease diagnostics, and a heightened emphasis on tailoring antifungal treatments to individual patient needs. Furthermore, prevailing trends expected to shape this market during the forecast period involve a greater adoption of molecular techniques for candida detection, an increased utilization of rapid nucleic acid amplification test (NAAT)-based testing, the growing incorporation of microbiome analysis into diagnostic workflows, the expansion of fungal diagnostic services within hospital settings, and a more pronounced focus on the early identification of fungal infections.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19356&type=smp
Candida Infection Testing Market Expansion Supported By Key Demand Factors
The candida infection testing market is anticipated to experience expansion fueled by a rise in yeast infection occurrences. These fungal infections, characterized by an overgrowth of candida and frequently impacting the mouth, genital regions, and skin, lead to symptoms like itching, redness, and general discomfort. The proliferation of candida, often triggered by disruptions in the body’s microbial balance, compromised immunity, or hormonal fluctuations, is the primary cause of these infections. Diagnostic testing for candida infections plays a crucial role in accurately identifying this overgrowth, enabling medical professionals to confirm the condition and determine the most effective treatment strategies. Illustrating this trend, data from the UK Health Security Agency revealed that in England, bloodstream infections attributed to yeast saw a 4% increase in 2024 compared to the preceding year, with reported cases climbing from 2,170 to 2,247, and the incidence rate rising from 3.8 to 3.9 per 100,000 individuals during the same timeframe. Consequently, the escalating prevalence of yeast infections is expected to be a significant driver for the candida infection testing market’s growth.
Candida Infection Testing Market Segment Outlook: Which Categories Are Expanding The Fastest?
The candida infection testing market covered in this report is segmented –
1) By Type: Invasive Candidiasis, Candidemia
2) By Test Type: Vaginal pH Test, Nucleic Acid Amplification Testing (NAAT), Microbiome Test
3) By Application: Hospital, Laboratory
Subsegments:
1) By Invasive Candidiasis: Tissue Biopsy Testing, Urine Culture Testing, Blood Culture Testing
2) By Candidemia: Blood Tests, Serological Testing, Molecular Testing
Candida Infection Testing Market Growth Trends Influencing Competitive Dynamics
The significant players within the candida infection testing market are prioritizing the creation of cutting-edge diagnostic tools, exemplified by the advancement of fully automated polymerase chain reaction (PCR) rapid tests designed to pinpoint candida, thereby boosting the precision of diagnoses and improving patient health. Such an automated PCR rapid test represents a sophisticated medical device that leverages PCR technology to swiftly and reliably identify Candida species in biological specimens. As an illustration, in May of 2024, Bosch Healthcare Solutions GmbH, a German firm specializing in medical technology, introduced a PCR test for the detection of candida auris, utilized with their Vivalytic platform, which facilitates complete automation for rapid testing results available in under an hour directly at the point of patient care. This sophisticated testing method permits immediate screening, standing in stark contrast to conventional culture techniques that require one to three days for results from central laboratories, consequently postponing diagnosis and therapeutic interventions. Engineered for practical use within healthcare environments, this test proves especially advantageous for individuals at elevated risk, facilitating prompt diagnosis and treatment initiation, which is crucial for mitigating the severe health threats posed by C. auris infections.
Candida Infection Testing Market Key Companies And Competitive Benchmarking
Major companies operating in the candida infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, Private MD Labs LLC
Access The Complete Candida Infection Testing Market Report:
https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report
Candida Infection Testing Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the candida infection testing market in 2025. The regions covered in the candida infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model